NCT03123263 is a clinical trial in Breast Cancer, sponsored by Texas Tech University Health Sciences Center, El Paso.

Who is sponsoring NCT03123263?

NCT03123263 is sponsored by Texas Tech University Health Sciences Center, El Paso.

What condition does NCT03123263 study?

NCT03123263 studies Breast Cancer.

Is NCT03123263 still recruiting?

NCT03123263 is currently completed. Last updated 9 September 2019.

Are results published for NCT03123263?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-09-09 · How we verify

NCT03123263

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer

Completed Results posted Last updated 9 September 2019

What this trial tests

trial in Breast Cancer in 60 participants. Completed in 26 February 2019.

Timeline

11 April 2017

Primary endpoint
26 February 2019

26 February 2019

Quick facts

Lead sponsor	Texas Tech University Health Sciences Center, El Paso
Status	Completed
Study type	OBSERVATIONAL
Enrollment	60
Start date	11 April 2017
Primary completion	26 February 2019
Estimated completion	26 February 2019
Sites	1 location across United States

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Texas Tech University Health Sciences Center, El Paso

Who can join

Adults 18 to 90, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

LVEF Primary · Baseline (prior to therapy), at 3-6 months (mid-therapy), and at 1 year (end of therapy)

LV ejection fraction

Group	Value	95% CI
Patients	65.4	± .844
LVEF at 3-6months	64.7	± .724
LVEF End of Therapy	62.2	± .81

Number of Participants Hospitalized for Cardiac Issues. Secondary · 1 year

any hospitalization for cardiac issues

Group	Value	95% CI
Hospitalizations Due to Cardiac Complications	0

Adverse events — posted to ClinicalTrials.gov

Time frame: 1 year. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Trastuzumab-treated Breast Cancer Patients

Serious: 2/60 (3%)

Deaths: 0/60

Serious adverse events (1 terms)

Reaction	System	Trastuzumab-treated Breast…
LVEF decline	Cardiac disorders	—

Most-reported serious reactions: LVEF decline.

Data from ClinicalTrials.gov NCT03123263 adverse events section.

Sponsor's own description

This study retrospectively looks at changes in Echocardiographic parameters while using transtuzumab

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Texas Tech University Health Sciences Center, El Paso trials

Trials by the same sponsor.

NCT06016465 — Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs? · EARLY_PHASE1 · recruiting
NCT05303116 — Do EEG and Neurocognitive Assessments Correlate With COVID Brainfog Symptoms? · completed
NCT05174988 — Reducing Postoperative Bleeding After Hysterectomy Via Independent Closure of Vaginal Cuff Angles · NA · completed
NCT05077917 — Cromolyn Sodium for Treatment of COVID-19 Pneumonia · Phase 3 · terminated
NCT04786379 — Surgical Management of Knee Septic Arthritis · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03123263 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Texas Tech University Health Sciences Center, El Paso
Last refreshed: 9 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03123263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing